- Investing Ideas
- /
- Swiss Biotech Stocks
Swiss Biotech Stocks
Results
16
Even though biotechnology stocks can be very risky, they can also offer some of the biggest rewards with huge profits on offer when you find the right one. The companies below all have reasonable balance sheets and value, giving the best chance of finding a gem.
16 companies
Roche Holding
Market Cap: CHF 280.2b
Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.
ROG
CHF 328.20
7D
-0.4%
1Y
27.9%
Novartis
Market Cap: CHF 210.3b
Researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
NOVN
CHF 109.60
7D
-0.5%
1Y
23.1%
Galderma Group
Market Cap: CHF 38.5b
Operates as a dermatology company worldwide.
GALD
CHF 162.10
7D
-1.2%
1Y
58.9%
Sandoz Group
Market Cap: CHF 24.9b
Develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide.
SDZ
CHF 57.84
7D
-1.3%
1Y
54.1%
Bachem Holding
Market Cap: CHF 4.5b
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
BANB
CHF 59.90
7D
0.8%
1Y
1.5%
Siegfried Holding
Market Cap: CHF 3.3b
Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.
SFZN
CHF 74.60
7D
0.5%
1Y
-24.9%
Cosmo Pharmaceuticals
Market Cap: CHF 1.7b
Focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.
COPN
CHF 105.20
7D
0%
1Y
63.9%
Tecan Group
Market Cap: CHF 1.6b
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.
TECN
CHF 128.50
7D
-0.9%
1Y
-36.4%
Kuros Biosciences
Market Cap: CHF 1.1b
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
KURN
CHF 27.48
7D
-0.8%
1Y
27.8%
Idorsia
Market Cap: CHF 1.1b
A biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada.
IDIA
CHF 4.26
7D
-3.8%
1Y
334.6%
PolyPeptide Group
Market Cap: CHF 861.1m
Operates as a contract development and manufacturing company in Europe, the United States, and India.
PPGN
CHF 26.10
7D
3.4%
1Y
-10.8%
Basilea Pharmaceutica
Market Cap: CHF 672.1m
A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.
BSLN
CHF 54.70
7D
-0.9%
1Y
31.8%
Newron Pharmaceuticals
Market Cap: CHF 476.1m
A biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States.
NWRN
CHF 23.85
7D
0.8%
1Y
170.7%
BioVersys
Market Cap: CHF 142.7m
A clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria.
BIOV
CHF 24.40
7D
-2.4%
1Y
n/a
Xlife Sciences
Market Cap: CHF 142.5m
Focuses on the development and commercialization of research projects in the life sciences sector.
XLS
CHF 24.70
7D
2.1%
1Y
-1.2%
Molecular Partners
Market Cap: CHF 126.6m
A clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.
MOLN
CHF 3.39
7D
-1.2%
1Y
-23.6%